Furthermore,
Trump wants dictate their prices:
An innovative anticancer drug from Roche. Moreover, Novartis costs the United States several times more than in our country … For example, for the moment. Therefore, Because the American president Trump wants to modify the balance of power on the global pharmaceutical market.
KEYSTONE
Last Thursday. Consequently, the American president did not only brandish the stick of customs duties again, taking Switzerland in particular. Therefore, He also sent letters to large pharmaceutical companies around the world. trump wants dictate their prices Consequently, He asked them to take immediate measures to lower the price of medicines in the United States. For example, Otherwise, the latter would be threatened with retaliatory measures. However, Trump still fixes a period of 60 days to companies.
Concretely, Trump is moving towards the controversial price model “Most Favoured Nation”. In addition, Already during the electoral campaign, he had once again announced wanting to impose this model. Its objective: in the future, the United States should not pay more than other countries. On the contrary, Trump simply wants to apply the lowest international price in the United States.
In 2020, Trump had already tried to implement this model by executive decree, but he had encountered legal obstacles. But with the 2024 electoral campaign, the subject returned, more lively and more determined than ever.
A challenge of several billion – Trump wants dictate their prices
For pharmaceutical groups like Roche and trump wants dictate their prices Novartis, this represents a challenge of several billion dollars. Basel’s first reactions are therefore neutral. “We are currently examining the letter,” wrote Novartis at the request of the AWP news agency. At Roche also, we said we were looking at the missive that US President Trump has published on social media.
Roche would be prepared for possible customs duties. confident in the fact that any possible impact could be managed: “with reinforced production capacities in the United States and proactive measures such as stock adjustment and technology transfers, we work to guarantee uninterrupted access to our products”.
To locate things: in its pharmaceutical division. Roche generated in the first half of 2025 just over half of its almost 24 billion turnover in the United States, or 12.7 billion. The diagnostic division generates almost a third of its turnover (S1: nearly 7 billion) in the United States. At trump wants dictate their prices his colleague Novartis. nearly 12 billion out of a total of 27 billion turnover in the first half came from the United States. If prices fell at European level, turnover could collapse by several billion.
It is therefore not surprising that these two groups. as well as other large ones in the branch, have clearly spoken in the past against prices fixed by the state. Their argument: innovation cannot be financed in this way.
The American government puts innovation in danger
Sectoral associations such as interpreharma condemn the model as dangerous for medical progress. With its decision on the “Most-Favoured-Nation Drug Pricing”. the US government jeopardizes the global supply of innovative drugs, writes interpharma in a first position. “Swiss pharmaceutical companies practicing research as well as supply to Switzerland are also affected”.
In the program “Forum” of the French-speaking Switzerland RTS. the spokesperson for the association Michèle trump wants dictate their prices Sierro recalled on Saturday that pharmaceutical companies decided themselves the price at which they sold their medicines in the United States. It also called on Switzerland to reform its own price fixing system. In our country, prices are set by the State. “We are asking for a reform of this system, because it is not suitable for innovative products,” said Ms. Sierro.
Investors pass pharmaceutical actions at the reel
Investor reactions have in any case been clear: both in the United States. in Europe, the pharmaceutical sector courses have dropped. With us. investors will not be able to react until tomorrow Monday, the scholarship having remained closed at the end of the week due to national holidays.
Analyst David Seigerman of BMO Capital Markets spoke of “big shocking titles”. but expressed doubts about the ease of implementing the requirements. There are legal obstacles. Richard Vosser de JPMorgan issued trump wants dictate their prices a similar opinion.
!function(f,b,e,v,n,t,s) {if(f.fbq)return;n=f.fbq=function(){n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}; if(!f._fbq)f._fbq=n;n.push=n;n.loaded=!0;n.version=’2.0′; n.queue=[];t=b.createElement(e);t.async=!0; t.src=v;s=b.getElementsByTagName(e)[0]; s.parentNode.insertBefore(t,s)}(window,document,’script’, ‘https://connect.facebook.net/en_US/fbevents.js’); fbq(‘init’, ‘817457858324581’); fbq(‘track’, ‘PageView’);
Further reading: Ebace: Geneva partially saves its business aviation fair – “We are witnessing an explosion of exchanges”: China bought a record gold amount from Russia – Earthquake in the automobile: Volvo changes shoulder rifle and abandons its all-electric strategy – The National Assembly’s commission of inquiry denounces the “failures” of the State – “Many children want to come”: a concrete plane built to travel the private Palestinians at airport.